No Data
UniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
Express News | UniQure Biopharma Granted Orphan Drug Designation For Its 'Adeno-associated Viral Vector Serotype 5 Encoding Human Alpha-galactosidase A' For The Treatment Of Fabry Disease
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $25
Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target
Express News | UniQure Doses First Patient In Phase I/IIa Clinical Trial Of AMT-191 For Fabry Disease
UniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know